Inspire Medical Systems stock plunges after results trigger analyst downgrades

Inspire Medical Systems (INSP) stock plunged 27% after reporting disappointing quarterly results and significantly cutting its 2025 revenue guidance to $900-910 million from the prior $940-955 million. This prompted four Wall Street firms, including JPMorgan and Truist, to downgrade the shares and sharply reduce price targets. Analysts cited concerns over challenges with the I-5 device launch, potential headwinds from GLP-1 weight loss drugs, upcoming competition, and execution issues, leading to skepticism regarding the company's near-term prospects despite management's 2026 growth projections.

Analysis

Inspire Medical Systems (INSP) experienced a severe 27% decline in its stock price following a significant downward revision of its 2025 revenue guidance. The company now projects revenue of $900-910 million, a substantial cut from the previous range of $940-955 million, which was already presented as conservative. This guidance miss prompted a coordinated loss of confidence from Wall Street, with four firms including JPMorgan and Truist Securities downgrading the stock to neutral/hold ratings and implementing sharp price target cuts; JPMorgan, for instance, lowered its target to $110 from $195. The negative revision is attributed to a combination of persistent operational and market-based headwinds, specifically a third delay in the Inspire V (I-5) device launch which raises execution concerns, potential demand erosion from GLP-1 weight loss drugs, looming competition, and internal account capacity constraints. Despite management's optimistic outlook for accelerated growth in 2026, analyst consensus remains skeptical about the company's near-term prospects due to deteriorating visibility and mounting execution risks.

Key Decisions for Investors

• Given the magnitude of the guidance cut and the series of analyst downgrades, investors holding INSP should critically reassess their position and risk tolerance, as the news signals fundamental challenges to the company's growth thesis.
• Potential investors should exercise extreme caution before buying on this dip, as the stock's plunge is rooted in operational failures and emerging market threats, not just a temporary market overreaction.
• Closely monitor future earnings calls for concrete evidence of progress on the delayed I-5 launch and for management's updated assessment of the impact from GLP-1 drugs, as these factors are now central to rebuilding credibility and establishing a floor for the stock.